← FDA DRUG APPROVALS
FDA ANDA · ANDA200180
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE
Sponsor: WATSON LABS
APPLICATION
ANDA200180
TYPE
ANDA
ORIGINAL APPROVAL
2011-01-12
LATEST ACTION
2026-01-15
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Discontinued
Products
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDEDiscontinued
HYDROCHLOROTHIAZIDE 12.5MG, LOSARTAN POTASSIUM 100MG · TABLET · ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDEDiscontinued
HYDROCHLOROTHIAZIDE 25MG, LOSARTAN POTASSIUM 100MG · TABLET · ORAL
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDEDiscontinued
HYDROCHLOROTHIAZIDE 12.5MG, LOSARTAN POTASSIUM 50MG · TABLET · ORAL
Approval history
2026-01-15Labeling · Supplement 4 · standardAP
2020-05-07Labeling · Supplement 2 · standardAP
2020-05-07Labeling · Supplement 3 · standardAP
2011-01-12UNKNOWN · OriginalAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.